Atossa Therapeutics (ATOS) Interest Coverage Ratio (2011 - 2026)
Atossa Therapeutics (ATOS) posted quarterly Interest Coverage Ratio of 53.44 for Q4 2025, down 9.85% year-over-year from 59.28 in Q4 2024, and down 157.59% quarter-over-quarter from 20.75 in Q3 2025.
Atossa Therapeutics (ATOS) Interest Coverage Ratio (2011 - 2026) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Interest Coverage Ratio for 15 consecutive years, with 53.44 the latest figure, recorded in Q4 2025.
- In Q4 2025, Interest Coverage Ratio fell 9.85% year-over-year to 53.44; the TTM figure through Dec 2025 stood at 62.01 (up 12.23% YoY), while the FY2025 annual figure was 92.85, down 9822.29% from the prior year.
- Interest Coverage Ratio eased to 53.44 in Q4 2025 per ATOS's latest filing, from 20.75 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 123.79 in Q4 2021 and bottomed at 538.77 in Q2 2021.
- Historically, Interest Coverage Ratio has averaged 121.54 across 5 years, with a median of 90.95 in 2022.
- Annual changes were most pronounced in 2021 — Interest Coverage Ratio jumped 137.21% — and 2025, when it slumped 11727.09%.
- Atossa Therapeutics' Interest Coverage Ratio stood at 123.79 in 2021, then plunged by 167.08% to 83.04 in 2022, then jumped by 33.37% to 55.33 in 2023, then increased by 12.08% to 48.65 in 2024, then decreased by 9.85% to 53.44 in 2025.
- Business Quant data shows ATOS's Interest Coverage Ratio at 53.44 in Q4 2025, 20.75 in Q3 2025, and 26.35 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 1.42 |
| 10 | Atossa Therapeutics | 22.79 Mn | 22.79 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -173.88 |
| Mar 31, 2026 | -186.23 |
| Dec 31, 2025 | -53.44 |
| Sep 30, 2025 | -20.75 |
| Jun 30, 2025 | -26.35 |
| Mar 31, 2025 | -98.85 |
| Dec 31, 2024 | -48.65 |
| Sep 30, 2024 | -1.05 |
| Jun 30, 2024 | -2.97 |
| Mar 31, 2024 | -0.84 |
| Dec 31, 2023 | -55.33 |
| Sep 30, 2023 | -240.90 |
| Jun 30, 2023 | -155.86 |
| Mar 31, 2023 | -126.75 |
| Dec 31, 2022 | -83.04 |
| Sep 30, 2022 | -241.32 |
| Jun 30, 2022 | -183.19 |
| Mar 31, 2022 | -139.62 |
| Dec 31, 2021 | 123.79 |
| Sep 30, 2021 | -429.83 |